Global Down syndrome Market
Global Down syndrome Market

Down syndrome Comprehensive Study by Type (Trisomy 21 (Nondisjunction), Mosaicism, Translocation), Disorder Severity (Mild Down Syndrome (IQ: 50–69), Moderate Down Syndrome (IQ: 35–50), Severe Down Syndrome (IQ: 20–35), Mosaic Down Syndrome (IQ: 10–30)), Treatment Programs (Speech Therapy, Physical Therapy, Occupational Therapy, Educational Therapy) Players and Region - Global Market Outlook to 2026

Down syndrome Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Nov 2021 Edition 209 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Down syndrome is a genetic disorder causes developmental and intelligence delays. The disorder caused by abnormal cell division which results into the extra genetic material from chromosome 21. This disorder could lead to thyroid and heart diseases, also associated with distinct facial expression, developmental and intelligence delays. This disorder is considered as a common chromosomal disorder. According to WHO Down syndrome is between 1 in 1,000 to 1 in 1,100 live births worldwide. In 20th century the babies with Down syndrome would rarely live past 9 year, but in 21th century thanks to advanced healthcare system and treatment people with this condition live up to 60 ageThis growth is primarily driven by One of the most premier scientific organization for researchers and clinicians studying Down syndrome is Trisomy 21 Research Society (T21RS)..

Globally, a noticeable market trend is evident Down syndromic induvial have a greater chances to develop Alzheimer’s-like dementia in early life stage as compared to induvial without Down syndrome, so that Rivastigmine, galantamine, memantine, and donepezil drugs have been used for the Down syndrome associated dementia (DSAD). Major Players, such as • AC Immune SA (Switzerland), Aelis Farma SAS (France), Alzheon Inc (United States), Avanti Biosciences Inc (United States), Eisai Co Ltd (japan), F. Hoffmann-La Roche Ltd (Switzerland), NeuroCircuit Therapeutics Inc (United States), NeuroNascent Inc (United States) and San Biotechnology Co Ltd (japan) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.



Market Drivers
  • One of the most premier scientific organization for researchers and clinicians studying Down syndrome is Trisomy 21 Research Society (T21RS).

Market Trend
  • Down syndromic induvial have a greater chances to develop Alzheimer’s-like dementia in early life stage as compared to induvial without Down syndrome, so that Rivastigmine, galantamine, memantine, and donepezil drugs have been used for the Down syndrome associated dementia (DSAD)

Restraints
  • Cannot be cured with Any Kind Of Drug Treatments or Surgery

Opportunities
Public domain companies can Increase investment in healthcare and research sector. and Sponsorships and funding to NGOs dedicated to Down syndrome therapy
Challenges
Children with Down syndrome more tend to face Hearing loss, Problems in eye, Heart problems, Obstructive sleep apnea, Leukaemia, Thyroid, early age Alzheimer’s and Blockage in the intestine

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Down syndrome Study Sheds Light on
— The Down syndrome Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Down syndrome industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Down syndrome industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What are the years considered in the Down syndrome Market?
Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026

2. Who are the key players profiled in the Down syndrome Market?
Companies that are profiled in Global Down syndrome Market are • AC Immune SA (Switzerland), Aelis Farma SAS (France), Alzheon Inc (United States), Avanti Biosciences Inc (United States), Eisai Co Ltd (japan), F. Hoffmann-La Roche Ltd (Switzerland), NeuroCircuit Therapeutics Inc (United States), NeuroNascent Inc (United States) and San Biotechnology Co Ltd (japan) etc.

3. What is Down syndrome Market?
Down syndrome is a genetic disorder causes developmental and intelligence delays. The disorder caused by abnormal cell division which results into the extra genetic material from chromosome 21. This disorder could lead to thyroid and heart diseases, also associated with distinct facial expression, developmental and intelligence delays. This disorder is considered as a common chromosomal disorder. According to WHO Down syndrome is between 1 in 1,000 to 1 in 1,100 live births worldwide. In 20th century the babies with Down syndrome would rarely live past 9 year, but in 21th century thanks to advanced healthcare system and treatment people with this condition live up to 60 age
Report Objectives / Segmentation Covered
By Type
  • Trisomy 21 (Nondisjunction)
  • Mosaicism
  • Translocation
By Disorder Severity
  • Mild Down Syndrome (IQ: 50–69)
  • Moderate Down Syndrome (IQ: 35–50)
  • Severe Down Syndrome (IQ: 20–35)
  • Mosaic Down Syndrome (IQ: 10–30)

By Treatment Programs
  • Speech Therapy
  • Physical Therapy
  • Occupational Therapy
  • Educational Therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. One of the most premier scientific organization for researchers and clinicians studying Down syndrome is Trisomy 21 Research Society (T21RS).
    • 3.3. Market Challenges
      • 3.3.1. Children with Down syndrome more tend to face Hearing loss, Problems in eye, Heart problems, Obstructive sleep apnea, Leukaemia, Thyroid, early age Alzheimer’s and Blockage in the intestine
    • 3.4. Market Trends
      • 3.4.1. Down syndromic induvial have a greater chances to develop Alzheimer’s-like dementia in early life stage as compared to induvial without Down syndrome, so that Rivastigmine, galantamine, memantine, and donepezil drugs have been used for the Down syndrome associated dementia (DSAD)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Down syndrome, by Type, Disorder Severity, Treatment Programs and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Down syndrome (Value)
      • 5.2.1. Global Down syndrome by: Type (Value)
        • 5.2.1.1. Trisomy 21 (Nondisjunction)
        • 5.2.1.2. Mosaicism
        • 5.2.1.3. Translocation
      • 5.2.2. Global Down syndrome by: Disorder Severity (Value)
        • 5.2.2.1. Mild Down Syndrome (IQ: 50–69)
        • 5.2.2.2. Moderate Down Syndrome (IQ: 35–50)
        • 5.2.2.3. Severe Down Syndrome (IQ: 20–35)
        • 5.2.2.4. Mosaic Down Syndrome (IQ: 10–30)
      • 5.2.3. Global Down syndrome by: Treatment Programs (Value)
        • 5.2.3.1. Speech Therapy
        • 5.2.3.2. Physical Therapy
        • 5.2.3.3. Occupational Therapy
        • 5.2.3.4. Educational Therapy
      • 5.2.4. Global Down syndrome Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Down syndrome (Price)
      • 5.3.1. Global Down syndrome by: Type (Price)
  • 6. Down syndrome: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. • AC Immune SA (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Aelis Farma SAS (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Alzheon Inc (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Avanti Biosciences Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eisai Co Ltd (japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. NeuroCircuit Therapeutics Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. NeuroNascent Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. San Biotechnology Co Ltd (japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Down syndrome Sale, by Type, Disorder Severity, Treatment Programs and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Down syndrome (Value)
      • 7.2.1. Global Down syndrome by: Type (Value)
        • 7.2.1.1. Trisomy 21 (Nondisjunction)
        • 7.2.1.2. Mosaicism
        • 7.2.1.3. Translocation
      • 7.2.2. Global Down syndrome by: Disorder Severity (Value)
        • 7.2.2.1. Mild Down Syndrome (IQ: 50–69)
        • 7.2.2.2. Moderate Down Syndrome (IQ: 35–50)
        • 7.2.2.3. Severe Down Syndrome (IQ: 20–35)
        • 7.2.2.4. Mosaic Down Syndrome (IQ: 10–30)
      • 7.2.3. Global Down syndrome by: Treatment Programs (Value)
        • 7.2.3.1. Speech Therapy
        • 7.2.3.2. Physical Therapy
        • 7.2.3.3. Occupational Therapy
        • 7.2.3.4. Educational Therapy
      • 7.2.4. Global Down syndrome Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Down syndrome (Price)
      • 7.3.1. Global Down syndrome by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Down syndrome: by Type(USD Million)
  • Table 2. Down syndrome Trisomy 21 (Nondisjunction) , by Region USD Million (2015-2020)
  • Table 3. Down syndrome Mosaicism , by Region USD Million (2015-2020)
  • Table 4. Down syndrome Translocation , by Region USD Million (2015-2020)
  • Table 5. Down syndrome: by Disorder Severity(USD Million)
  • Table 6. Down syndrome Mild Down Syndrome (IQ: 50–69) , by Region USD Million (2015-2020)
  • Table 7. Down syndrome Moderate Down Syndrome (IQ: 35–50) , by Region USD Million (2015-2020)
  • Table 8. Down syndrome Severe Down Syndrome (IQ: 20–35) , by Region USD Million (2015-2020)
  • Table 9. Down syndrome Mosaic Down Syndrome (IQ: 10–30) , by Region USD Million (2015-2020)
  • Table 10. Down syndrome: by Treatment Programs(USD Million)
  • Table 11. Down syndrome Speech Therapy , by Region USD Million (2015-2020)
  • Table 12. Down syndrome Physical Therapy , by Region USD Million (2015-2020)
  • Table 13. Down syndrome Occupational Therapy , by Region USD Million (2015-2020)
  • Table 14. Down syndrome Educational Therapy , by Region USD Million (2015-2020)
  • Table 15. South America Down syndrome, by Country USD Million (2015-2020)
  • Table 16. South America Down syndrome, by Type USD Million (2015-2020)
  • Table 17. South America Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 18. South America Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 19. Brazil Down syndrome, by Type USD Million (2015-2020)
  • Table 20. Brazil Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 21. Brazil Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 22. Argentina Down syndrome, by Type USD Million (2015-2020)
  • Table 23. Argentina Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 24. Argentina Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 25. Rest of South America Down syndrome, by Type USD Million (2015-2020)
  • Table 26. Rest of South America Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 27. Rest of South America Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 28. Asia Pacific Down syndrome, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Down syndrome, by Type USD Million (2015-2020)
  • Table 30. Asia Pacific Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 31. Asia Pacific Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 32. China Down syndrome, by Type USD Million (2015-2020)
  • Table 33. China Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 34. China Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 35. Japan Down syndrome, by Type USD Million (2015-2020)
  • Table 36. Japan Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 37. Japan Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 38. India Down syndrome, by Type USD Million (2015-2020)
  • Table 39. India Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 40. India Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 41. South Korea Down syndrome, by Type USD Million (2015-2020)
  • Table 42. South Korea Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 43. South Korea Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 44. Australia Down syndrome, by Type USD Million (2015-2020)
  • Table 45. Australia Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 46. Australia Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Down syndrome, by Type USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 50. Europe Down syndrome, by Country USD Million (2015-2020)
  • Table 51. Europe Down syndrome, by Type USD Million (2015-2020)
  • Table 52. Europe Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 53. Europe Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 54. Germany Down syndrome, by Type USD Million (2015-2020)
  • Table 55. Germany Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 56. Germany Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 57. France Down syndrome, by Type USD Million (2015-2020)
  • Table 58. France Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 59. France Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 60. Italy Down syndrome, by Type USD Million (2015-2020)
  • Table 61. Italy Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 62. Italy Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 63. United Kingdom Down syndrome, by Type USD Million (2015-2020)
  • Table 64. United Kingdom Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 65. United Kingdom Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 66. Netherlands Down syndrome, by Type USD Million (2015-2020)
  • Table 67. Netherlands Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 68. Netherlands Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 69. Rest of Europe Down syndrome, by Type USD Million (2015-2020)
  • Table 70. Rest of Europe Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 71. Rest of Europe Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 72. MEA Down syndrome, by Country USD Million (2015-2020)
  • Table 73. MEA Down syndrome, by Type USD Million (2015-2020)
  • Table 74. MEA Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 75. MEA Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 76. Middle East Down syndrome, by Type USD Million (2015-2020)
  • Table 77. Middle East Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 78. Middle East Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 79. Africa Down syndrome, by Type USD Million (2015-2020)
  • Table 80. Africa Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 81. Africa Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 82. North America Down syndrome, by Country USD Million (2015-2020)
  • Table 83. North America Down syndrome, by Type USD Million (2015-2020)
  • Table 84. North America Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 85. North America Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 86. United States Down syndrome, by Type USD Million (2015-2020)
  • Table 87. United States Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 88. United States Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 89. Canada Down syndrome, by Type USD Million (2015-2020)
  • Table 90. Canada Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 91. Canada Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 92. Mexico Down syndrome, by Type USD Million (2015-2020)
  • Table 93. Mexico Down syndrome, by Disorder Severity USD Million (2015-2020)
  • Table 94. Mexico Down syndrome, by Treatment Programs USD Million (2015-2020)
  • Table 95. Down syndrome: by Type(USD/Units)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Down syndrome: by Type(USD Million)
  • Table 106. Down syndrome Trisomy 21 (Nondisjunction) , by Region USD Million (2021-2026)
  • Table 107. Down syndrome Mosaicism , by Region USD Million (2021-2026)
  • Table 108. Down syndrome Translocation , by Region USD Million (2021-2026)
  • Table 109. Down syndrome: by Disorder Severity(USD Million)
  • Table 110. Down syndrome Mild Down Syndrome (IQ: 50–69) , by Region USD Million (2021-2026)
  • Table 111. Down syndrome Moderate Down Syndrome (IQ: 35–50) , by Region USD Million (2021-2026)
  • Table 112. Down syndrome Severe Down Syndrome (IQ: 20–35) , by Region USD Million (2021-2026)
  • Table 113. Down syndrome Mosaic Down Syndrome (IQ: 10–30) , by Region USD Million (2021-2026)
  • Table 114. Down syndrome: by Treatment Programs(USD Million)
  • Table 115. Down syndrome Speech Therapy , by Region USD Million (2021-2026)
  • Table 116. Down syndrome Physical Therapy , by Region USD Million (2021-2026)
  • Table 117. Down syndrome Occupational Therapy , by Region USD Million (2021-2026)
  • Table 118. Down syndrome Educational Therapy , by Region USD Million (2021-2026)
  • Table 119. South America Down syndrome, by Country USD Million (2021-2026)
  • Table 120. South America Down syndrome, by Type USD Million (2021-2026)
  • Table 121. South America Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 122. South America Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 123. Brazil Down syndrome, by Type USD Million (2021-2026)
  • Table 124. Brazil Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 125. Brazil Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 126. Argentina Down syndrome, by Type USD Million (2021-2026)
  • Table 127. Argentina Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 128. Argentina Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 129. Rest of South America Down syndrome, by Type USD Million (2021-2026)
  • Table 130. Rest of South America Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 131. Rest of South America Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 132. Asia Pacific Down syndrome, by Country USD Million (2021-2026)
  • Table 133. Asia Pacific Down syndrome, by Type USD Million (2021-2026)
  • Table 134. Asia Pacific Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 135. Asia Pacific Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 136. China Down syndrome, by Type USD Million (2021-2026)
  • Table 137. China Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 138. China Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 139. Japan Down syndrome, by Type USD Million (2021-2026)
  • Table 140. Japan Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 141. Japan Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 142. India Down syndrome, by Type USD Million (2021-2026)
  • Table 143. India Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 144. India Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 145. South Korea Down syndrome, by Type USD Million (2021-2026)
  • Table 146. South Korea Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 147. South Korea Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 148. Australia Down syndrome, by Type USD Million (2021-2026)
  • Table 149. Australia Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 150. Australia Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Down syndrome, by Type USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 154. Europe Down syndrome, by Country USD Million (2021-2026)
  • Table 155. Europe Down syndrome, by Type USD Million (2021-2026)
  • Table 156. Europe Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 157. Europe Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 158. Germany Down syndrome, by Type USD Million (2021-2026)
  • Table 159. Germany Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 160. Germany Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 161. France Down syndrome, by Type USD Million (2021-2026)
  • Table 162. France Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 163. France Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 164. Italy Down syndrome, by Type USD Million (2021-2026)
  • Table 165. Italy Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 166. Italy Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 167. United Kingdom Down syndrome, by Type USD Million (2021-2026)
  • Table 168. United Kingdom Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 169. United Kingdom Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 170. Netherlands Down syndrome, by Type USD Million (2021-2026)
  • Table 171. Netherlands Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 172. Netherlands Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 173. Rest of Europe Down syndrome, by Type USD Million (2021-2026)
  • Table 174. Rest of Europe Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 175. Rest of Europe Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 176. MEA Down syndrome, by Country USD Million (2021-2026)
  • Table 177. MEA Down syndrome, by Type USD Million (2021-2026)
  • Table 178. MEA Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 179. MEA Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 180. Middle East Down syndrome, by Type USD Million (2021-2026)
  • Table 181. Middle East Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 182. Middle East Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 183. Africa Down syndrome, by Type USD Million (2021-2026)
  • Table 184. Africa Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 185. Africa Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 186. North America Down syndrome, by Country USD Million (2021-2026)
  • Table 187. North America Down syndrome, by Type USD Million (2021-2026)
  • Table 188. North America Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 189. North America Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 190. United States Down syndrome, by Type USD Million (2021-2026)
  • Table 191. United States Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 192. United States Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 193. Canada Down syndrome, by Type USD Million (2021-2026)
  • Table 194. Canada Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 195. Canada Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 196. Mexico Down syndrome, by Type USD Million (2021-2026)
  • Table 197. Mexico Down syndrome, by Disorder Severity USD Million (2021-2026)
  • Table 198. Mexico Down syndrome, by Treatment Programs USD Million (2021-2026)
  • Table 199. Down syndrome: by Type(USD/Units)
  • Table 200. Research Programs/Design for This Report
  • Table 201. Key Data Information from Secondary Sources
  • Table 202. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Down syndrome: by Type USD Million (2015-2020)
  • Figure 5. Global Down syndrome: by Disorder Severity USD Million (2015-2020)
  • Figure 6. Global Down syndrome: by Treatment Programs USD Million (2015-2020)
  • Figure 7. South America Down syndrome Share (%), by Country
  • Figure 8. Asia Pacific Down syndrome Share (%), by Country
  • Figure 9. Europe Down syndrome Share (%), by Country
  • Figure 10. MEA Down syndrome Share (%), by Country
  • Figure 11. North America Down syndrome Share (%), by Country
  • Figure 12. Global Down syndrome: by Type USD/Units (2015-2020)
  • Figure 13. Global Down syndrome share by Players 2020 (%)
  • Figure 14. Global Down syndrome share by Players (Top 3) 2020(%)
  • Figure 15. Global Down syndrome share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. • AC Immune SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. • AC Immune SA (Switzerland) Revenue: by Geography 2020
  • Figure 19. Aelis Farma SAS (France) Revenue, Net Income and Gross profit
  • Figure 20. Aelis Farma SAS (France) Revenue: by Geography 2020
  • Figure 21. Alzheon Inc (United States) Revenue, Net Income and Gross profit
  • Figure 22. Alzheon Inc (United States) Revenue: by Geography 2020
  • Figure 23. Avanti Biosciences Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Avanti Biosciences Inc (United States) Revenue: by Geography 2020
  • Figure 25. Eisai Co Ltd (japan) Revenue, Net Income and Gross profit
  • Figure 26. Eisai Co Ltd (japan) Revenue: by Geography 2020
  • Figure 27. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 29. NeuroCircuit Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. NeuroCircuit Therapeutics Inc (United States) Revenue: by Geography 2020
  • Figure 31. NeuroNascent Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. NeuroNascent Inc (United States) Revenue: by Geography 2020
  • Figure 33. San Biotechnology Co Ltd (japan) Revenue, Net Income and Gross profit
  • Figure 34. San Biotechnology Co Ltd (japan) Revenue: by Geography 2020
  • Figure 35. Global Down syndrome: by Type USD Million (2021-2026)
  • Figure 36. Global Down syndrome: by Disorder Severity USD Million (2021-2026)
  • Figure 37. Global Down syndrome: by Treatment Programs USD Million (2021-2026)
  • Figure 38. South America Down syndrome Share (%), by Country
  • Figure 39. Asia Pacific Down syndrome Share (%), by Country
  • Figure 40. Europe Down syndrome Share (%), by Country
  • Figure 41. MEA Down syndrome Share (%), by Country
  • Figure 42. North America Down syndrome Share (%), by Country
  • Figure 43. Global Down syndrome: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • • AC Immune SA (Switzerland)
  • Aelis Farma SAS (France)
  • Alzheon Inc (United States)
  • Avanti Biosciences Inc (United States)
  • Eisai Co Ltd (japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • NeuroCircuit Therapeutics Inc (United States)
  • NeuroNascent Inc (United States)
  • San Biotechnology Co Ltd (japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation